



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Product Information

Description:	Recombinant human TSLP (thymic stromal lymphopoietin), encompassing amino acids 29-159. This construct contains mutations R127A and R130A that impact the putative furin cleavage site present in the protein. This construct contains a C-terminal Avi-tag™ followed by a His-tag (6xHis).
Background:	TSLP (thymic stromal lymphopoietin) is a protein that functions as a type I cytokine, as an alarmin and growth factor in the immune system. It is involved in type 2 immune responses, T _H 2 (T helper 2 cells) responses, and the maturation and recruitment of dendritic cells (DCs), T cells, B cells, neutrophils, mast cells, and other lymphoid cells. It can be produced by epithelial and stromal cells in lung, skin, and gastric system, but also by DCs, basophils and mast cells. Its expression can be induced by infections, pro-inflammatory cytokines, proteases, and even mechanical injury. For instance, it can be produced in the lungs in response to infection with influenza or rhinovirus. Its role as alarmin can result in increasing inflammation. TSLP is linked to allergic reactions such as asthma, atopic dermatitis, and food allergies, by inducing the expression of OX40L, CD80 and CD86 and stimulating CD4 ⁺ T cells. The mutations R127A and R130A function to remove a putative furin site and further stabilize the full-length protein in HEK293 cells. In 2021, the TSLP-neutralizing antibody tezepelumab was approved for the treatment of severe asthma. Targeting TSLP is an active area of investigation with ongoing clinical trials for the treatment of autoimmune disorders.
Species:	Human
Construct:	TSLP (R127A, R130A) (29-159-Avi-His)
Concentration:	1.12 mg/ml
Expression System:	HEK293
Purity:	≥90%
Endotoxin Level:	55.3 EU/mg
Format:	Aqueous buffer solution.
Formulated In:	8 mM phosphate, pH7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
MW:	18.1 kDa + glycans
Glycosylation:	This protein runs at a higher MW by SDS-PAGE due to glycosylation.
Genbank Accession:	NM_033035.5
Stability:	At least 6 months at -80°C.
Storage:	-80°C
Instructions for Use:	Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.
Assay Conditions:	Assay was done according to TSLPR:TSLP [Biotinylated] Small Molecule Inhibitor Screening Chemiluminescence Assay Kit (BPS Bioscience #82698) with various concentrations of TSLP (R127A, R130A), Avi-His-Tag Recombinant protein.
Applications:	Useful for binding assays.

Quality Control Data

4-20% SDS-PAGE Coomassie Staining



TSLPR/TSLP (R127A, R130A) Binding Activity

